From the1Division of Diabetes, University of Texas Health Science Center, San Antonio, Texas; the2MedStar Research Institute, Hyattsville, Maryland; and3Amylin Pharmaceuticals, San Diego, California. Address correspondence and reprint requests to Alain D. Baron, MD, Amylin Pharmaceuticals, 9360 Towne Centre Dr., Suite 110, San Diego, CA 92121. E-mail: abaron@amylin.com. Received for publication 27 September 2004 and accepted in revised form 1 February 2005.R.A.D. is a member of advisory panels for Bristol Myers Squibb, Takeda, Eli Lilly, Novartis, and Amylin Pharmaceuticals; has received honoraria from Bristol Myers Squibb, Takeda, Novartis, and Amylin Pharma-ceuticals; and is the recipient of grants from Bristol Myers Squibb, Takeda, Eli Lilly, Novartis, and AmylinPharmaceuticals. R.E.R. is the recipient of grants from Amylin Pharmaceuticals and Eli Lilly. Abbreviations: GLP-1, glucagon-like peptide 1.